BAMOMAB

BamOmaB was founded in 2006 in order to provide newly developed, high-quality reagents for immunological research to the scientific community. These reagents primarily include novel monoclonal antibodies and ELISA-kits developed in the Department of Immunology of the University of Tuebingen.